"The National Weather Service’s most recent three-month outlook showed above-average temperatures for nearly the entire country. It predicts far above-average temperatures for the West, the Northeast and the Southeast."..
2:15.."While there was no statistically significant difference demonstrated in overall survival, the median overall survival (mOS) favored the binimetinib arm."
"Array Cocktail Reception with Investors and Analysts
06/05/16 6:00 p.m. CT
Please join Array BioPharma for a cocktail reception during the annual meeting of the American Society of Clinical Oncology in Chicago where you will be able to mingle with Array executive management and a number of key opinion leaders in the melanoma and colorectal cancer fields.
This event is NOT an official program of the ASCO Annual Meeting. RSVP"
"Had RRC been willing to engage with Taseko at the outset, it is possible these needless costs and distractions could have been avoided."..
Maybe we can sue to get our money back.."Co expects the defense costs for the RRC initiated lawsuit, regulatory complaint and proxy contest itself to be ~$4.5 mln."..
More like hate in this case..if the board changes..nothing will get done..no changes..common holders take a hit..bond holders I guess win..screw rr..
TT did not import unallowed losses from last years Passive Activity Loss (form 8582) worksheet 6, column (b). Maybe because I used h&r last year to save some bucks? Anyone else have to manual enter from 8582?
Options expire tomorrow..3000 $2 put contracts..some trader working the system..
"Pierre Fabre is the 3rd largest French pharmaceutical group. In 2013, its sales reached #$%$2.008 Billion, with international revenues accounting for 56%. Founded and headquartered in the southwest of France, Pierre Fabre currently has branches in 44 countries and distribution agreements in over 130 countries.
Covering all aspects of healthcare, from prescription drugs and OTC products to dermo-cosmetics, Pierre "Fabre Laboratories employ over 10,000 people worldwide. In 2013, Pierre Fabre allocated more than 17% of its drug revenues to R&D, focusing on three main areas: oncology, dermatology and neuropsychiatry."
as of 2013..PIERRE FABRE
PHARMACEUTICALS Total patents: 187
Patents/applications for patents: 2094
Won't be Novartis..3/31/15.."Array BioPharma shares have surged in the wake of the company's oncology deal with Novartis and the good news is expected to continue, said the company's CEO Ron Squarer. Squarer said he has high expectations following Array's agreement with Novartis in which the company regained full rights to a previously partnered Phase 3 oncology drug program (binimetinib), and acquired a second Phase 3 oncology program (encorafenib). In addition to an expected regulatory filing for binimetinib in the first half of 2016, Squarer anticipates filing for a uveal melanoma drug (selumetinib) in which it partnered with AstraZeneca."
"Reports Q3 (Sep) loss of $0.27 per share, $0.04 better than the Capital IQ Consensus of ($0.31); revenues rose 34.9% year/year to $8.5 mln vs the $8.24 mln Capital IQ Consensus. During the quarter, 25 additional XT-8 analyzers were placed in end-user laboratories, resulting in a total installed base of 616 analyzers within the U.S. market.
Co issues in-line guidance for FY15, sees FY15 revs of $38-40 mln vs. $38.51 mln Capital IQ Consensus Estimate. The Company now expects to place more than 90 XT-8 analyzers for the full year."
"Explanation of Responses:
1. The Vanguard Natural Resources, LLC ("VNR") Board of Directors approved the option for the VNR
management team and Independent Board of Directors to receive VNR common units in lieu of 2015 cash
compensation. Scott Smith elected this option and under the plan received a quarterly grant of VNR common units
instead of his fourth quarter 2015 full cash compensation. The unit price is calculated by using the weighted average
closing price of the month prior to the grant."
8/26/15.."BP’s Whiting refinery, the largest refinery in the Midwest, made a quicker-than-expected return to action this week. BP released a statement saying that the large crude distillation tower that went offline and caused gasoline prices to spike in the Midwest has “safely restarted,” and that output would ramp up over time."..
Should LRE change there mind..it will be a nice extra dividend check for us..from 8-K..
"The Merger Agreement contains certain termination rights for both Vanguard and LRE and further provides that, upon termination of the Merger Agreement, under certain circumstances, either party may be required to reimburse the other party’s expenses up to $1,215,000, and LRE may be required to pay Vanguard a termination fee equal to $7,288,000."